Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

• Status: Completed
• Trial end date: 2009-10-01

Summary

To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder

• Phase: Phase 3

Details

• Lead Sponsor: Pfizer
• Treatments: Fesoterodine; Tolterodine Tartrate